Teva Shared Data From Ongoing Phase 1b Study Of TEV-’408 Showing Improvements In Skin Pigmentation In Active Or Stable Non-Segmental Vitiligo Patients; Plans To Advance TEV-’408 Into Phase 2b Study In Vitiligo In Q4 2026

뉴스 본문을 불러오고 있어요.

Teva Shared Data From Ongoing Phase 1b Study Of TEV-’408 Showing Improvements In Skin Pigmentation In Active Or Stable Non-Segmental Vitiligo Patients; Plans To Advance TEV-’408 Into Phase 2b Study In Vitiligo In Q4 2026 | 웨이프 WAPE

Teva Shared Data From Ongoing Phase 1b Study Of TEV-’408 Showing Improvements In Skin Pigmentation In Active Or Stable Non-Segmental Vitiligo Patients; Plans To Advance TEV-’408 Into Phase 2b Study In Vitiligo In Q4 2026

기사 요약

관련 종목

댓글 —